AUS
NZ
UK
CA
USA
IND
Highlights:
- NATlab platform begins pre-clinical validation at a leading European infectious disease institute.
- Achieved 97% sensitivity in detecting positive samples, surpassing similar diagnostic systems.
- ADOR Diagnostics secures $1 million grant to develop NATlab application for stomach ulcer detection.
BATM Advanced Communications Ltd (LSE:BVC) has announced significant progress in its NATlab diagnostic platform, marking a pivotal step toward its commercialisation and regulatory approval. The company revealed that the system has entered pre-clinical validation at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, following successful trials in Israel.
Revolutionising Diagnostics
The NATlab platform represents a cutting-edge solution in the diagnostics space, designed to rapidly detect multiple pathogens from a single test. Its patented technology amplifies and identifies disease markers with exceptional precision, achieving a 97% sensitivity rate during initial evaluations.
The system’s speed and accuracy have outperformed comparable diagnostic platforms, positioning it as a promising tool for healthcare providers aiming to tackle infectious diseases efficiently.
Validation and Market Entry
The pre-clinical validation at the Rome-based institute is expected to pave the way for NATlab’s entry into the European Union (EU) market. This milestone aligns with BATM’s strategy to meet EU regulatory standards and initiate commercial sales. The company anticipates strong interest from healthcare providers and industry partners, driven by the platform’s ability to deliver rapid, multiplex diagnostics.
Innovation in Stomach Ulcer Diagnostics
In addition to its infectious disease applications, BATM’s associate company, ADOR Diagnostics, has secured a $1 million grant from the Israel Innovation Authority. The funding will support the development of a NATlab application specifically for diagnosing stomach ulcers. This project will unfold over two years, with milestones guiding its progression.
Leadership Commentary
Moti Nagar, Chief Executive of BATM, expressed optimism about the platform’s development and future prospects. "The commencement of the pre-clinical validation phase at a major European hospital is an important milestone in the development of NATlab and represents a key stage towards enabling its market entry,” he said.
Nagar highlighted the system's successful pre-clinical trials and growing industry awareness of its capabilities. He added, "We remain excited about its prospects and look forward to reporting on further progress."
Outlook
With its innovative technology and ongoing support from key grants and partnerships, BATM’s NATlab platform is set to make significant strides in the diagnostics industry. The company’s focus on precision, speed, and versatility positions NATlab as a solution capable of transforming how infectious diseases and other conditions are detected and managed globally.
